Alzheimer’s disease in the real world: Where evidence matters most
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring...
In just a few years, artificial intelligence (AI) has become a trusted tool in early drug...
In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic...
When we introduced HealthVerity eXOs, an agentic AI platform powered by Medeloop, in our recent...
The evolution of heart failure treatment and research Heart failure remains one of the most...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Digital health innovators and pharma leaders are under increasing pressure to show that new models...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically, w...